GlassScriptPhysician profile
Katrina D Kemp
NPI 1104944396
$16,962.44
in general payments reported to CMS, 2019-2025
26 companies · $3,707 in 2025
The $3,707 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,745 · 2022: $3,294 · 2023: $3,398 · 2024: $3,818 · 2025: $3,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,923.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,236.33 | 2021-2025 | Evenity, Krystexxa, Prolia |
| Ucb, INC. | $2,191.35 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,551.69 | 2021-2025 | |
| Janssen Biotech, INC. | $1,498.21 | 2021-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $1,288.08 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $1,143.10 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,065.91 | 2021-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $833.66 | 2021-2025 | Orencia |
| Pfizer INC. | $751.98 | 2021-2025 | |
| Horizon Therapeutics Plc | $543.09 | 2021-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $515.68 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $463.34 | 2021-2025 | Acthar |
| Radius Health, INC. | $444.72 | 2021-2025 | Tymlos |
| Lilly USA, LLC | $358.04 | 2021-2025 | Taltz, Zepbound, Olumiant |
| Aurinia Pharma U.S., INC. | $357.79 | 2021-2025 | Lupkynis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.80 | 2021-2025 | Ofev |
| Genentech USA, INC. | $180.14 | 2021-2025 | Actemra |
| Fresenius Kabi USA, LLC | $93.23 | 2023-2025 | Idacio, Tyenne |
| Sandoz INC. | $69.29 | 2023-2025 | Hyrimoz |
| Scilex Pharmaceuticals INC. | $42.34 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $39.14 | 2024 | Arcalyst |
| Bioventus LLC | $20.46 | 2025 | Durolane |
| Almatica Pharma LLC | $19.60 | 2024 | Teriparatide, Loreev Xr |
| Sobi, INC | $18.38 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $18.06 | 2023 | Arcalyst |
| Organon LLC | $16.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Kemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.